Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ES101 in Advanced Malignant Thoracic Tumors
NCT04841538Phase 2Withdrawn
- Sponsor
- Elpiscience
- Start
- Jul 2021
- Primary completion
- Dec 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 2, open-label trial of inbrx-105 in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and thoracic neoplasms (TN) (6 cohorts), sponsored by Elpiscience. Primary endpoints: Frequency and severity of adverse events, Recommended Phase 2 Dose at 6 months and 1 more. Planned start Jul 2021; status: withdrawn.
02
Drugs
inbrx-105
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)thoracic neoplasms (TN)
Beyond the preview
Go deeper on NCT04841538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04841538.